The research agenda for global mental health and substance-use disorders has been
largely driven by the exigencies of high health burdens and associated unmet needs in low …

Pathologic alcohol use affects more than 2 billion people and accounts for nearly 6% of all
deaths worldwide. There are three medications approved for the treatment of alcohol use …

Chronic heavy alcohol use impacts all major neurotransmitter systems and is associated
with multiple medical, psychiatric, and social problems. Available evidence‐based …

Alcohol use disorder is a complex syndrome with multiple treatment points including drug-
induced pathology, withdrawal management, behavioral/cognitive strategies, and relapse …

Background The development of alcohol dependence is associated with significant
morbidity and mortality. For the majority of affected people the most appropriate goal, in …

Alcohol use disorder (AUD) is the most prevalent substance use disorder worldwide.
Acamprosate and naltrexone are anti-craving drugs used in AUD pharmacotherapy …

Abstract Background and Aims Depression and anxiety are often comorbid with alcoholism
and contribute to craving and relapse. We aimed to estimate the prevalence of life‐time …

For more than 25 years, advances have been made in develo** medications to treat
alcohol use disorder (AUD), highlighted by the US Food and Drug Administration's approval …

Naltrexone can aid in reducing alcohol consumption, while acamprosate supports
abstinence; however, not all patients with alcohol use disorder (AUD) benefit from these …

Neurobiological processes underlying the epidemiologically established link between
alcohol and several types of social, aggressive, and violent behavior remain poorly …